Description
Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.
Product information
Molecular Weight: 629.03
Formula: C29H28ClF3N8O3
Smiles: CC1=NC(=CN=C1N1C[C@@H](C)[C@@H](C)C1=O)C(C)N1C=C(C=N1)NC(=O)C1=NC(=CN=C1CO)C1=C(C=CC(Cl)=C1F)C(F)F
InChiKey: JLHFPSCOGXXAFT-UIDSBSESSA-N
InChi: InChI=1S/C29H28ClF3N8O3/c1-13-10-40(29(44)14(13)2)27-15(3)37-20(8-35-27)16(4)41-11-17(7-36-41)38-28(43)25-22(12-42)34-9-21(39-25)23-18(26(32)33)5-6-19(30)24(23)31/h5-9,11,13-14,16,26,42H,10,12H2,1-4H3,(H,38,43)/t13-,14-,16?/m1/s1
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: To be determined
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
References:
- Ram W. Sabnis, et al. Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy. ACS Med Chem Lett. 2022 Mar 4;13(4):528-529.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.
